Top Suppliers:I want be here


112727-80-7

112727-80-7 structure
112727-80-7 structure
  • Name: Renzapride
  • Chemical Name: 4-amino-N-(1-azabicyclo[3.3.1]nonan-4-yl)-5-chloro-2-methoxybenzamide
  • CAS Number: 112727-80-7
  • Molecular Formula: C16H22ClN3O2
  • Molecular Weight: 323.81800
  • Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
  • Create Date: 2018-04-20 08:00:00
  • Modify Date: 2025-09-02 23:57:25
  • Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist[1]. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study[2].

Name 4-amino-N-(1-azabicyclo[3.3.1]nonan-4-yl)-5-chloro-2-methoxybenzamide
Synonyms MK-0646
Renzaprida
Renzapride
Renzapridum
Description Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist[1]. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study[2].
Related Catalog
Target

5-HT4 Receptor:115 nM (Ki)

In Vitro Renzapride replaces specific binding of [H3] GR 113808 (a selective 5-HT receptor antagonist) to cloned human 5-HT4 receptors with a Ki value of 115 nM[3].
In Vivo Renzapride (BRL 24924) (100 µg i.v.) results in a partial reverse of both the delayed solid and liquid meals emptying[2]. Renzapride (BRL 24924) (0.5-1 mg/kg) significantly increases the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach[4]. Animal Model: Dog (simulating gastroparesis)[2] Dosage: 100 µg/kg Administration: i.v. Result: Results in a partial reverse of both the delayed solid and liquid meals emptying. Animal Model: Mice (30-45g)[2] Dosage: 0.5-1 mg/kg Administration: p.o. Result: Significantly increase the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach.
References

[1]. Camilleri M, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(10):895-904.

[2]. Scarpellini E, et al. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(11):1663-1670.

[3]. Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999;39(5):375-382.

[4]. Mawe GM, et al. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol. 1989;257(3 Pt 1):G386-G396.

Density 1.3g/cm3
Boiling Point 469.2ºC at 760mmHg
Molecular Formula C16H22ClN3O2
Molecular Weight 323.81800
Flash Point 237.6ºC
Exact Mass 323.14000
PSA 67.59000
LogP 3.05490
Vapour Pressure 5.6E-09mmHg at 25°C
Index of Refraction 1.614
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.